Newsletter Edition #386 [The Files In-Depth]
Readers,
In today's edition, we look at the "upstream" challenges in responding to the Ebola outbreak in the Democratic Republic of Congo. These contribute to reflections on preparedness, financing and the response to health emergencies.
Issues including decisions around the scope of pathogens, the access to information, and what constitutes "benefits". They speak to the ongoing negotiations on the Pathogen Access Benefit Sharing System at the WHO.
My colleague Anne Jomard raises three questions to examine the difficulties in meeting the objectives of the 100-day mission - to have vaccines ready for initial authorisation and manufacturing at scale within 100 days of a threat being identified. She pieces together what did not work, and why.
Thank you for feedback and engagement.
Geneva Health Files offers value to our readers who are experts in global health. Tracking global health policy-making in Geneva is tough and expensive, without institutional support. For six years, we have provided you with the information and tools that directly contribute to your work in the field. We rely on our readers who value news they can use.
By becoming a paying subscriber you make our work possible and help us gather, report and synthesise global health intelligence.
Best,
Priti
Priti Patnaik, Founder & Publisher, Geneva Health Files
Feel free to write to us: genevahealthfiles@gmail.com ; Find us on BlueSky, Instagram and Linkedin.
Presenting our weekly in-depth analysis on global health that captures the big picture and the nuances like no one else does. This is an exclusive edition for our subscribers.
I. ANALYSIS:
Three Questions the Bundibugyo Ebola Outbreak Asks of CEPI’s 100 Days Mission
By Anne Jomard
Priti Patnaik contributed to this story.
Jomard is a biological research scientist, who has made a transition into journalism, focusing on stories that link science, public health and policy. She is a Geneva Health Files Fellow for 2026. She can be reached at: write@annejomard.com
Ramping up investments, and scurrying for countermeasures in the midst of an expanding health emergency was never going be easy. It was not supposed to be this way.
An array of complex factors have meant that the international community and local actors have not been able to act fast enough to keep pace with the ongoing Ebola outbreak in the Democratic Republic of the Congo - the 17th such outbreak on the record.
In this story, we take a closer look at the 100-day mission that aims to have vaccines ready for initial authorisation and manufacturing at scale within 100 days of a threat being identified. The current outbreak raises at least three questions.
